Drug Trial Radar · NCT01127750
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
Last checked: Nov 20, 2026Latest source record: Feb 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,417
Actual
Start
May 2010
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.
Conditions
- Relapsing Multiple Sclerosis
Interventions
FTY720Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability profile of FTY720 in patients with relapsing forms of MSTime frame: 4 months
Locations
289 sites in 23 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Box Hill, Australia
Novartis Investigative Site
Heidelberg, Australia
Novartis Investigative Site
Kogarah, Australia
Novartis Investigative Site
Liverpool, Australia
Novartis Investigative Site
Woodville South, Australia
Novartis Investigational Site
Linz, Austria
Novartis Investigational Site
Vienna, Austria
Novartis Investigational Site
Vienna, Austria
Novartis Investigational Site
Bruges, Belgium
Novartis Investigational Site
Brussels, Belgium
Novartis Investigational Site
Brussels, Belgium
Novartis Investigational Site
Charleroi, Belgium
Novartis Investigational Site
Leuven, Belgium
Novartis Investigational Site
Melsbroek, Belgium
Novartis Investigational Site
Overpelt, Belgium
Novartis Investigational Site
Sijsele, Belgium
Novartis Investigational Site
Tinlot, Belgium
Novartis Investigational Site
Wilrijk, Belgium
Novartis Investigational Site
Montreal, Canada
Novartis Investigational Site
Québec, Canada
Novartis Investigational Site
Victoria, Canada
Novartis Investigational Site
Prague, Czechia
Novartis Investigational Site
Teplice, Czechia
Novartis Investigational Site
Aarhus, Denmark
Novartis Investigational Site
Copenhagen, Denmark
Novartis Investigational Site
Helsinki, Finland
Novartis Investigational Site
Turku, Finland
Novartis Investigational Site
Aachen, Germany
Novartis Investigative Site
Aachen, Germany
Novartis Investigational Site
Aalen, Germany
Novartis Investigational Site
Abensberg, Germany
Novartis Investigational Site
Achim, Germany
Novartis Investigational Site
Alzenau in Unterfranken, Germany
Novartis Investigational Site
Aschaffenburg, Germany
Novartis Investigational Site
Attenberg, Germany
Novartis Investigational Site
Augsburg, Germany
Novartis Investigational Site
Bad Honnef, Germany
Novartis Investigational Site
Bad Krozingen, Germany
Novartis Investigative Site
Bad Mergentheim, Germany
Novartis Investigational Site
Bad Neustadt / Saale, Germany
Showing 40 of 289 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.